{"prompt": "['Carbomer and Carboxymethyleellulose', '209510', 'Clinical Protocol V1.0', 'Results in death', 'Is life-threatening', 'The term \"life-threatening\\' in the definition of \\'serious\\' refers to an event in which', 'the subject was at risk of death at the time of the event. It does not refer to an', 'event, which hypothetically might have caused death, if it were more severe;', 'Requires inpatient hospitalization or prolongation of existing hospitalization', 'In general, hospitalization signifies that the subject has been detained (usually', 'involving at least an overnight stay) at the hospital or emergency ward for', 'observation and/or treatment that would not have been appropriate in the', \"physician's office or outpatient setting. Complications that occur during\", 'hospitalization are AEs. If a complication prolongs hospitalization or fulfills any', 'other serious criteria, the event is serious. When in doubt as to whether', '\"hospitalization\" occurred, or was necessary, the AE should be considered', 'serious.', 'Hospitalization for elective treatment of a pre-existing condition that did not', 'worsen from baseline is not considered an AE.', 'Results in persistent or significant disability/incapacity', \"The term disability means a substantial disruption of a person's ability to conduct\", 'normal life functions.', 'This definition is not intended to include experiences of relatively minor medical', 'significance such as uncomplicated headache, nausea, vomiting, diarrhea,', 'influenza, and accidental trauma (e.g. sprained ankle) which may interfere with or', 'prevent everyday life functions but do not constitute a substantial disruption', 'Results in congenital anomaly/birth defect', 'Other situations:', 'Medical or scientific judgment should be exercised in deciding whether SAE', 'reporting is appropriate in other situations such as important medical events that', 'may not be immediately life-threatening or result in death or hospitalization but', 'may jeopardize the subject or may require medical or surgical intervention to', 'prevent one of the other outcomes listed in the above definition. These events', 'should usually be considered serious.', 'Examples of such events include invasive or malignant cancers, intensive', 'treatment in an emergency room or at home for allergic bronchospasm, blood', 'dyscrasias or convulsions that do not result in hospitalization, or development of', 'drug dependency or drug abuse.', \"Note: Classification of an AE as 'serious' is based on the outcome of the event, and is a factor\", 'in determining reporting requirements.', '10.3', 'Reporting of Adverse Events', '10.3.1', 'Reporting Period', 'All AEs, and therefore all SAEs will be collected immediately after a subject consents to', 'participate in the study by the completion (signature) of the ICF and until 5 days following last', 'administration of the study product (or last procedure).', 'Medical occurrences that began before obtaining informed consent will be recorded in the', 'Medical History/Current Medical Conditions section of the CRF not the AE section.', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 40 of 65']['Carbomer and Carboxymethyleellulose', '209510', 'Clinical Protocol V1.0', 'Details recorded by the subject on a diary or similar document that meet the definition of an AE', 'must also be discussed with the subjects and transcribed in the AE section of the CRF.', '10.4', 'Reporting Procedures', 'The investigator and any designees are responsible for detecting, documenting and reporting', 'events that meet the definition of an AE and remain responsible for following up on AEs that', 'are serious, considered related to the study product(s), participation in the study, or a study', 'procedure, or that caused the subject to discontinue the study product or study.', 'The investigator (or medically qualified designee) is to report all directly observed AEs and all', 'AEs spontaneously reported by the study subject. In addition, each study subject will be', 'questioned about AEs.', 'Each AE is to be assessed to determine if it meets the criteria for a SAE. If an SAE occurs,', 'expedited reporting will follow local and international regulations, as appropriate.', 'When an AE occurs, it is the responsibility of the investigator (or medically qualified designee)', 'to review all documentation (e.g. hospital progress notes, laboratory, and diagnostics reports)', 'related to the event.', 'The investigator or site staff will then record all relevant information regarding an AE in the', 'CRF and all details relating to an SAE in the paper SAE Form provided.', 'It is not acceptable for the investigator (or medically qualified designee) to send photocopies', \"of the subject's medical records to GSK CH in lieu of completion of the AE CRF page/SAE\", 'form.', 'There may be instances when copies of medical records for certain cases are requested by GSK', 'CH. In this instance, all subject identifiers, with the exception of the subject number, will be', 'redacted on the copies of the medical records prior to submission to GSK CH.', 'The investigator (or medically qualified designee) will attempt to establish a diagnosis of the', 'event based on signs, symptoms, and/or other clinical information. The diagnosis will be the', 'documented as the AE/SAE where known and not the individual signs/symptoms. (e.g. upper', 'respiratory tract infection, seasonal allergy, etc. instead of runny nose).', 'AEs elicited by the investigator (or medically qualified designee) in a standard manner at the', 'study visits should also be recorded in the AE section of the CRF and/or using the SAE form', '(subject to the classification of the AE). Care will be taken not to introduce bias when', 'questioning a subject about any changes in their health. Open-ended and non-leading verbal', 'questioning should be used.', '10.4.1', 'Reporting of an Adverse Event', 'All AEs will be reported on the AE page of the CRF by the investigator or site staff. It should', 'be noted that the form for collection of SAE information is not the same as the AE CRF. Where', 'the same data are collected, the AE CRF page and the SAE form must be completed in a', 'consistent manner. For example, the same AE term should be used on both. AEs should be', 'reported using concise medical terminology on the CRF as well as on the form for collection of', 'SAE information.', '10.4.2', 'Reporting of a Serious Adverse Event', 'In addition to recording the details of each AE on the AE CRF page, an SAE form should be', 'completed, as fully as possible. Hard copies of the \"paper\\' SAE form will be provided in the', 'GlaxoSmithKline Consumer Healthcare Confidential', 'Template Version Effective: 18-May-18 (CCR #11475)', 'Page 41 of 65']\n\n###\n\n", "completion": "END"}